Latest News

It will be difficult for passive investors to overlook this hassle-free opportunity.

The Galleri test failed its primary endpoint in a landmark trial, but that doesn't mean it doesn't have a big future.

Riot Platforms stock soared 57% in May. A nuclear power partnership stole the show.

Medtronic is on track to reverse after a major market meltdown driven by fear. The upside potential is double-digit, not including the dividend.

The SpaceX IPO is expected to happen next week.

This European frozen foods leader reported a notable insider buy amid steady demand and strong distribution across major supermarket chains.

Nvidia hasn't had the strongest 2026 so far.

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

Broadcom's AI chip news isn't as bad for Sandisk as you might have heard.

Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026.

An above-average boost is likely on the way.

Microsoft's AI business is booming in multiple aspects.

GitLab is well-positioned to drive growth long-term as its agentic push gains traction. Clients reliant on compliance and security turn to GitLab.

The cancer test maker could still have a bright future.

As long as AI hyperscalers continue to increase their spending, the chipmaker will thrive.

Everyone hates Broadcom stock today, and Micron is getting caught in the storm.

Toro (TTC) Q2 2026 Earnings Transcript

Investors are getting mixed messages regarding this well-watched company.

Redwire's latest contract probably isn't massive financially, but it highlights its engineering expertise.

This only takes a few minutes, and it's well worth your time.

Movie theaters are having their strongest year since 2019. Patrons are back. Investors should follow.

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?

Many people struggling with excess weight are searching for effective solutions that go beyond traditional dieting and exercise. One medication gaining att

Toro (NYSE:TTC) raised its full-year outlook after reporting stronger-than-expected fiscal second-quarter results, with executives pointing to broad demand across its professional and residential businesses, improving margins and benefits from its productivity initiatives. Chairman and Chief Execut

X-Energy (NASDAQ:XE) used its first earnings call as a public company to outline progress on its advanced nuclear reactor and fuel businesses, while reporting higher first-quarter revenue and grant income tied to its federal cost-share program. The company began trading on the Nasdaq on April 24 an